Self‐Supplied Reactive Oxygen Species‐Responsive Mitoxantrone Polyprodrug for Chemosensitization‐Enhanced Chemotherapy under Moderate Hyperthermia
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202303631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Hongjie Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Materials Science, University of Science and Technology of China, 96 Jinzhai Road, Hefei, Anhui, 230026, P. R. China. Hauptthemen laut MEDLINE: Mitoxantrone, Reactive Oxygen Species. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Beijing Health Promotion Association, Fundamental Research Funds for the Central Universities, the Innovation and Entrepreneurship Support Program.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Currently, the secondary development and modification of clinical drugs has become one of the research priorities. Researchers have developed a variety of TME‐responsive nanomedicine carriers to solve certain clinical problems. Unfortunately, endogenous stimuli such as reactive oxygen species (ROS), as an important prerequisite for effective therapeutic efficacy, are not enough to achieve the expected drug release process, therefore, it is difficult to achieve a continuous and efficient treatment process. Herein, a self‐supply ROS‐responsive cascade polyprodrug (PMTO) is designed. The encapsulation of the chemotherapy drug mitoxantrone (MTO) in a polymer backbone could effectively reduce systemic toxicity when transported in vivo. After PMTO is degraded by endogenous ROS of the TME, another part of the polyprodrug backbone becomes cinnamaldehyde (CA), which can further enhance intracellular ROS, thereby achieving a sustained drug release process. Meanwhile, due to the disruption of the intracellular redox environment, the efficacy of chemotherapy drugs is enhanced. Finally, the anticancer treatment efficacy is further enhanced due to the mild hyperthermia effect of PMTO. In conclusion, the designed PMTO demonstrates remarkable antitumor efficacy, effectively addressing the limitations associated with MTO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Materials Science, University of Science and Technology of China, 96 Jinzhai Road, Hefei, Anhui, 230026, P. R. China.
- State Key Laboratory of Fire Science, University of Science and Technology of China, 443 Huangshan Road, Hefei, Anhui, 230026, P. R. China.
- The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, 230001, P. R. China.
ORCID-Profile: Yuan Hu
Förderung
- Beijing Health Promotion Association
- Fundamental Research Funds for the Central Universities
- the Innovation and Entrepreneurship Support Program
Zitieren
APA
Zhang, H., Wang, J., Wu, R., Zheng, B., Sang, Y., Wang, B., Song, L., Hu, Y., & Ma, X. (2024). Self‐Supplied Reactive Oxygen Species‐Responsive Mitoxantrone Polyprodrug for Chemosensitization‐Enhanced Chemotherapy under Moderate Hyperthermia. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202303631
Vancouver
Zhang H, Wang J, Wu R, Zheng B, Sang Y, Wang B, et al. Self‐Supplied Reactive Oxygen Species‐Responsive Mitoxantrone Polyprodrug for Chemosensitization‐Enhanced Chemotherapy under Moderate Hyperthermia. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202303631
BibTeX
@article{Zhang2024,
author = {Zhang, Hongjie and Wang, Jing and Wu, Ruiying and Zheng, Benyan and Sang, Yanxiang and Wang, Bibo and Song, Lei and Hu, Yuan and Ma, Xiaopeng},
title = {Self‐Supplied Reactive Oxygen Species‐Responsive Mitoxantrone Polyprodrug for Chemosensitization‐Enhanced Chemotherapy under Moderate Hyperthermia},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202303631}
}
EUVIMED